A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor: AbbVie
This PHASE1 trial investigates Advanced Solid Tumors Cancer and is currently completed. AbbVie leads this study, which shows 18 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
18 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Completed PHASE1
▶ Show 13 earlier versions
-
Jan 2023 — Feb 2023 [monthly]
Completed PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Apr 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2022 — Mar 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Aug 2020 — Nov 2020 [monthly]
Recruiting PHASE1
-
Mar 2020 — Aug 2020 [monthly]
Recruiting PHASE1
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2020 — Feb 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
- Idera Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Barcelona, Spain , Berlin, Germany , Bordeaux, France , Buffalo, United States , Chicago, United States , Detroit, United States , Erlangen, Germany , Fuenlabrada, Spain , Haifa, Israel and 15 more locations